CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Experimental: Hyper-CVAD + Calaspargase pegol Treatment

Participants will receive calaspargase pegol administered over 1 hour with each cycle of Hyper-CVAD, mini-CVD, and late intensification, beginning with Cycle 1B. Responding patients will have dose reduction of HyperCVAD for Cycles 2B-4B. Participants with CD20+ ALL will also be given Rituximab once per cycle.

Drug: Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy)

Hyper-CVAD consists of two combinations of drugs (courses A and B) given in an alternating fashion. The term “hyper” refers to the hyperfractionated nature of the chemotherapy, which is given in small doses, more frequently, to minimize side effects. CVAD is the acronym of the drugs in course a: cyclophosphamide, vincristine, doxorubicin and dexamethasone.

Course A: Cyclophosphamide days 1, 2 and 3. Vincristine days 4 and 11, Doxorubicin day 4, dexamethasone days 1-4 and 11-14, Cytarabine day 7. Mesna is also given orally with cyclophosphamide, to reduce the incidence of haemorrhagic cystitis, a common side effect of cyclophosphamide. Methotrexate, an antimetabolite, may be given when necessary to get chemotherapy past the blood brain barrier.

Course B: Methotrexate Day 1 and Cytarabine Days 2 and 3. Dosage is individualized to the patient.

Drug: Calaspargase Pegol

Calaspargase pegol 2000 IU/m^2 (capped at 3750 IU) will be administered beginning in cycle 1B of Hyper-CVAD, and will continue at this dose for the duration of the trial.

Other Names:

  • Asparlas
  • CalPeg

Drug: Rituximab

Rituximab 375mg/m^2 will be administered once per cycle for patients with CD20+ ALL.

Other Name: Rituxan

Source: View full study details on

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

October 17, 2022Comments | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine